Choose Your Country or Region

Acyclovir (Aciclovir)

Name: Acyclovir (Aciclovir)
Brand: Selleck Chemicals
SKU: S1807
Rating: 5 (16 reviews)

Synonyms: Acycloguanosine, ACV, NSC 645011,BW 248U

Catalog No.S1807 Purity: 99.93%

Acyclovir (Aciclovir) is a synthetic nucleoside analogue active against herpesviruses. Acyclovir induces cell cycle perturbation and apoptosis in Jurkat leukemia cells.

Acyclovir (Aciclovir) Chemical Structure

CAS: 59277-89-3

Selleck's Acyclovir (Aciclovir) has been cited by 16 Publications

1 Customer Review

Purity & Quality Control

Batch: Purity: 99.93%

99.93

Related compound libraries

Choose Selective Antiviral Inhibitors

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
BSC-1 cells	Function assay		Antiviral activity of the compound was evaluated against the Herpes simplex virus type-1 in BSC-1 cells, IC50=2.6 μM	2913300
P3HR-1 cells	Function assay		Effective concentration for the inhibition of Epstein-Barr virus EBV-DNA synthesis in human lymphoblastoid P3HR-1 cells, EC50=6.75 μM	12408726
HFF cells	Function assay		Concentration for HSV-1 plaque reduction (VPR) by 50% in HFF cells, EC50=1.1 μM	14584954
HFF cells	Function assay		Inhibitory concentration required to reduce HSV-1 induced cytopathogenic effect (CPE) by 50 % in HFF cells, EC50=2.22 μM	14584954
human embryonic lung cells	Function assay		Antiviral activity was measured as effective concentration required to reduce Varicella Zoster virus (OKA)-induced plaque formation in human embryonic lung cells, EC50=1.1 μM	11549457
HEL cells	Function assay		Compound was tested for anti-viral activity against HSV-1(G) in HEL cells, EC50=1.3 μM	14643328
HEL cell	Function assay		Effective concentration required to inhibit Tyrosine kinase (TK+) Varicella-Zoster virus-induced cytopathicity by 50% in OKA strain HEL cell lines, EC50=4.53 μM	11495586
HSV-2 MS Vero cells	Function assay		Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell monolayers of HSV-2 MS Vero cells by 50%, EC50=6.2 μM	11585457
HSV-1 E-377 Vero cells	Function assay		Inhibition of plaque formation in monolayers of HSV-1 E-377 Vero cells by 50%, EC50=4.4 μM	11585457
HSV-1 KOS Vero cells	Function assay		Inhibition of plaque formation in monolayers of HSV-1 KOS Vero cells by 50%, EC50=2.2 μM	11585457
HeLa cell	Function assay		Ability to inhibit cytopathogenicity of herpes simplex type 1 virus (G) in HeLa cell culture, IC50=0.19 μM	11356110
HEp-2 cells	Function assay		Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus-1 (K979) in HEp-2 cells	2842506
HeLa cells	Function assay		Inhibition of HSV-1 DNA synthesis in virus-infected HeLa cells, IC50=1.9 μM	7752206
human HFF cells	Function assay		Inhibitory concentration of the drug against the cytopathic effect for E-377 strain of herpes simplex virus-1 (HSV-1) in human HFF cells, EC50=0.04 μM	8394933
human HFF cells	Function assay		Inhibitory concentration of the drug against the cytopathic effect for MS strain of herpes simplex virus-2 (HSV-2) in human HFF cells, EC50=0.09 μM	8394933
MRC-5 cells	Function assay		Antiviral activity in plaque reduction assay was determined against herpes simplex virus type 2 (HSV-2) in MRC-5 cells, IC50=2.5 μM	2153202
human lung fibroblasts (MRC-5)	Function assay		Compound was tested for antiviral activity against Herpes Simplex virus Type-1(18189) in human lung fibroblasts (MRC-5)	3040998
Raji cells	Function assay		Inhibitory concentration of the drug against the antigen production against P3HR-1 strain of epstein barr virus-2 (EBV) in Raji cells, EC50=2.9 μM	8394933
Vero cells	Function assay		Inhibitory activity against herpes simplex virus type 2 (HSV 2) strain 186 in Vero cells, IC50=1.7 μM	8576922
BSC-1 cells	Function assay		Effective concentration required to inhibit herpes simplex virus 1 in BSC-1 cells in ELISA, EC50=1.5 μM	15634003
HFF cells	Function assay		Effective concentration required to inhibit varicella zoster virus replication in HFF cells, EC50=1.6 μM	15634003
HFF cells	Function assay		Effective concentration required to inhibit herpes simplex virus 1 in HFF cells in cytopathic effect (CPE) assay, EC50=0.9 μM	15634003
Daudi cells	Function assay		Inhibition of EBV replication in Daudi cells by viral capsid antigen-ELISA, EC50=0.33 μM	17004726
african green monkey Vero cells	Function assay	48 h	Antiviral activity against HSV2 strain 333 infected in african green monkey Vero cells assessed as inhibition of cytopathic effect after 48 hrs by plaque reduction assay, EC50=1.87 μM	22704890
WI-38 cell	Function assay		Anti viral activity against VZV(pplla strain) in WI-38 cell monolayers, ID50=4 μM	1316966
HEL cells	Function assay	4 days	Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days, EC50=0.2 μM	22459876
HEL cells	Function assay		Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50=0.14 μM	23099097
African green monkey Vero 76 cells	Cytotoxicity assay	48-96 h	Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining, CC50=13 μM	26119992
Click to View More Cell Line Experimental Data

Biological Activity

Description

Acyclovir (Aciclovir) is a synthetic nucleoside analogue active against herpesviruses. Acyclovir induces cell cycle perturbation and apoptosis in Jurkat leukemia cells.

Targets

HSV ^[1]

In vitro
In vitro	Acyclovir sensitivity of herpes simplex virus isolates is determined in a plaque-reduction assay in Vero cells. IC50 Values are consistently 2-3 fold lower in B2 compared with the H strain of Vero cells. HSV Type 2 strains are 2-10-fold less sensitive than Type 1 strains^[2].

In Vivo
In vivo	low-dose oral acyclovir may be effective in the prevention of HSV infection during OKT3 treatment of seropositive patients. Continuation of acyclovir prophylaxis for two to four weeks following the conclusion of OKT3 therapy may prevent occurrence of delayed infections^[3].

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-01-11)
NCT05589688	Not yet recruiting	Obesity	University Hospital Toulouse	January 2024	Phase 1
NCT06058858	Not yet recruiting	Cytomegalovirus Infections\|Acute Leukemia\|B Cell Lymphoma	Assistance Publique - Hôpitaux de Paris	October 1 2023	--
NCT05468619	Recruiting	Herpes Simplex	National Institute of Allergy and Infectious Diseases (NIAID)	September 23 2022	Phase 1
NCT05198570	Recruiting	Herpesviridae Infections\|Herpes Simplex 1\|Varicella Zoster Virus Infection\|Transplantation Infection\|Oncology	University of Pisa\|IRCCS Burlo Garofolo	September 15 2021	--

References

Chemical lnformation & Solubility

Molecular Weight	225.2	Formula	C₈H₁₁N₅O₃
CAS No.	59277-89-3	SDF	Download Acyclovir (Aciclovir) SDF
Smiles	C1=NC2=C(N1COCCO)N=C(NC2=O)N
Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years-20°Cpowder		1 month-20°Cin solvent

In vitro
Batch:

DMSO : 45 mg/mL ( (199.82 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):